---
title: "Viking Therapeutics 盤前大跌超 30% 消息面上公司口服減肥藥的研究試驗數據不及預期。"
description: "Viking Therapeutics 盤前大跌超 30% 消息面上公司口服減肥藥的研究試驗數據不及預期。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/253641074.md"
published_at: "2025-08-19T12:29:42.000Z"
---

# Viking Therapeutics 盤前大跌超 30% 消息面上公司口服減肥藥的研究試驗數據不及預期。

Viking Therapeutics 盤前大跌超 30% 消息面上公司口服減肥藥的研究試驗數據不及預期。

### Related Stocks

- [VKTX.US - Viking治療](https://longbridge.com/zh-HK/quote/VKTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Appetite for weight-loss deals broader than visible, Viking CEO says | Viking Therapeutics CEO Brian Lian stated that interest in weight-loss drug deals is broader than it seems, as pharmaceu | [Link](https://longbridge.com/zh-HK/news/272335070.md) |
| Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Pipeline in New Corporate Presentation | Viking Therapeutics Inc. has unveiled a corporate presentation highlighting advancements in its pipeline for metabolic a | [Link](https://longbridge.com/zh-HK/news/272603256.md) |
| Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients | Viking Therapeutics Inc. reported that its Phase 2 VENTURE trial of VK2735, a dual GLP-1/GIP receptor agonist, resulted  | [Link](https://longbridge.com/zh-HK/news/272265172.md) |
| Viking Therapeutics Completes Enrollment for VK2735 Obesity Maintenance Dosing Study | Viking Therapeutics Inc. has completed patient enrollment for its VK2735 obesity maintenance dosing study, which evaluat | [Link](https://longbridge.com/zh-HK/news/271927891.md) |
| Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today | An investment of $100 in Viking Therapeutics (NASDAQ:VKTX) 5 years ago would be worth $634.13 today, reflecting an avera | [Link](https://longbridge.com/zh-HK/news/270795937.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。